Compassionate use of recombinant human IL-7-hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma.

Stephen AhnJae-Sung ParkHeewon KimMinkyu HeoYoung Chul SungSin-Soo Jeun

Published in: Cancer medicine (2022)

Our study reports that IL-7 immunotherapy can restore and maintain TLC during treatment with various salvage chemotherapies in recurrent GBM patients without serious toxicity.

Keyphrases

recombinant human
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
oxidative stress
prognostic factors
emergency department
combination therapy